JP2017502920A5 - - Google Patents

Info

Publication number

JP2017502920A5

JP2017502920A5 JP2016524999A JP2016524999A JP2017502920A5 JP 2017502920 A5 JP2017502920 A5 JP 2017502920A5 JP 2016524999 A JP2016524999 A JP 2016524999A JP 2016524999 A JP2016524999 A JP 2016524999A JP 2017502920 A5 JP2017502920 A5 JP 2017502920A5

Authority

JP

Japan

Prior art keywords

binding fragment

pharmaceutical composition

antigen

antibody

seq

Prior art date

2014-10-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108010056102 CD100 antigen Proteins 0.000 claims description 42
• 102100027744 Semaphorin-4D Human genes 0.000 claims description 42
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 29
• 239000000427 antigen Substances 0.000 claims description 27
• 102000036639 antigens Human genes 0.000 claims description 27
• 108091007433 antigens Proteins 0.000 claims description 27
• 239000012634 fragment Substances 0.000 claims description 27
• 210000001130 astrocyte Anatomy 0.000 claims description 21
• 230000001404 mediated effect Effects 0.000 claims description 18
• 208000024891 symptom Diseases 0.000 claims description 16
• 208000024827 Alzheimer disease Diseases 0.000 claims description 10
• 210000002569 neuron Anatomy 0.000 claims description 9
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
• 102100034384 Plexin-B1 Human genes 0.000 claims description 6
• 101710100559 Plexin-B1 Proteins 0.000 claims description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
• 208000010877 cognitive disease Diseases 0.000 claims description 6
• 208000028698 Cognitive impairment Diseases 0.000 claims description 5
• 230000008499 blood brain barrier function Effects 0.000 claims description 5
• 210000001218 blood-brain barrier Anatomy 0.000 claims description 5
• 208000023105 Huntington disease Diseases 0.000 claims description 4
• 230000006378 damage Effects 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 210000004248 oligodendroglia Anatomy 0.000 claims description 4
• 206010003591 Ataxia Diseases 0.000 claims description 3
• 201000010374 Down Syndrome Diseases 0.000 claims description 3
• 206010061296 Motor dysfunction Diseases 0.000 claims description 3
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 3
• 208000018737 Parkinson disease Diseases 0.000 claims description 3
• 102100034383 Plexin-B2 Human genes 0.000 claims description 3
• 101710100551 Plexin-B2 Proteins 0.000 claims description 3
• 102000005157 Somatostatin Human genes 0.000 claims description 3
• 108010056088 Somatostatin Proteins 0.000 claims description 3
• 230000004913 activation Effects 0.000 claims description 3
• 230000007529 anxiety like behavior Effects 0.000 claims description 3
• 208000011235 central nervous system lupus Diseases 0.000 claims description 3
• 230000007850 degeneration Effects 0.000 claims description 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
• 208000035475 disorder Diseases 0.000 claims description 3
• 230000000694 effects Effects 0.000 claims description 3
• 230000003993 interaction Effects 0.000 claims description 3
• 230000006742 locomotor activity Effects 0.000 claims description 3
• 230000023105 myelination Effects 0.000 claims description 3
• 230000016273 neuron death Effects 0.000 claims description 3
• 235000016709 nutrition Nutrition 0.000 claims description 3
• 230000001737 promoting effect Effects 0.000 claims description 3
• 230000011664 signaling Effects 0.000 claims description 3
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
• 229960000553 somatostatin Drugs 0.000 claims description 3
• 230000006886 spatial memory Effects 0.000 claims description 3
• 210000000130 stem cell Anatomy 0.000 claims description 3
• 230000000946 synaptic effect Effects 0.000 claims description 3
• 230000003399 chemotactic effect Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 25
• 208000027866 inflammatory disease Diseases 0.000 claims 3
• 210000005036 nerve Anatomy 0.000 claims 3
• 238000012423 maintenance Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 102000006386 Myelin Proteins Human genes 0.000 claims 1
• 108010083674 Myelin Proteins Proteins 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
• 210000005012 myelin Anatomy 0.000 claims 1
• 238000000034 method Methods 0.000 description 51
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 8
• 230000014950 maintenance of blood-brain barrier Effects 0.000 description 4
• 230000006870 function Effects 0.000 description 2
• 230000002314 neuroinflammatory effect Effects 0.000 description 2
• 206010044688 Trisomy 21 Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 208000027061 mild cognitive impairment Diseases 0.000 description 1
• 230000008569 process Effects 0.000 description 1